Elicio Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $26,016 | $12,894 |
| Restricted cash, current | 1,318 | 722 |
| Prepaid expenses and other current assets | 3,312 | 2,732 |
| Total current assets | 30,646 | 16,348 |
| Property and equipment, net | 523 | 717 |
| Operating lease, right-of-use assets | 5,926 | 6,563 |
| Restricted cash, noncurrent | 693 | 685 |
| Other long-term prepaid assets | 600 | 2,833 |
| Total assets | $38,388 | $27,146 |
| Liabilities and stockholders’ (deficit) equity | ||
| Current liabilities | ||
| Accounts payable | $1,984 | $4,369 |
| Accrued expenses | 4,852 | 3,757 |
| Deferred research obligation | 1,307 | 694 |
| Operating lease liability, current | 877 | 910 |
| Unvested option exercise liability, current | — | 25 |
| Total current liabilities | 9,020 | 9,755 |
| Warrant liabilities | 23,181 | 11 |
| Operating lease liability, noncurrent | 5,338 | 6,007 |
| Convertible note - related party | 19,835 | — |
| Total liabilities | 57,374 | 15,773 |
| Stockholders' (deficit) equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.01 par value; 300,000,000 shares authorized; 10,798,832 shares and 9,618,178 shares issued at September 30, 2024 and December 31, 2023, respectively; 10,784,377 and 9,603,723 outstanding as of September 30, 2024 and December 31, 2023, respectively | 108 | 96 |
| Treasury stock, at cost, 14,455 shares outstanding | (150) | (150) |
| Additional paid-in capital | 161,355 | 153,827 |
| Accumulated other comprehensive loss | (202) | (197) |
| Accumulated deficit | (180,097) | (142,203) |
| Total stockholders' (deficit) equity | (18,986) | 11,373 |
| Total liabilities and stockholders' (deficit) equity | $38,388 | $27,146 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.